General Purposes The general purposes of the Committee are to: • Develop the Company’s overall executive compensation philosophy and objectives; • Discharge the Board’s responsibilities relating to compensation of the Company’s executive officers and, further, to assist the Board in the discharge of its fiduciary responsibilities with regard to establishment of policies governing, and the implementation of, all aspects of remuneration throughout the Company, including benefits and perquisites of executive officers of the Company and any other employees designated by the Committee as key employees of the Company and its subsidiaries; • Discharge similar responsibilities with respect to the remuneration of non-employee directors; • Review and discuss with management the Company’s disclosures in the Compensation Discussion and Analysis (the “CD&A”) required by rules and regulations of the Securities and Exchange Commission (the “SEC”) and recommend to the Board whether the CD&A should be included in the Company’s proxy statement or other applicable SEC filings; • Prepare a Compensation Committee Report for inclusion in the Company’s applicable filings with the SEC that complies with the rules and regulations of the SEC; and • Provide policy guidance and oversight on significant human resource policies and practices. Review and Discuss the CD&A and Compensation Committee Report. • With the assistance of management and any outside advisers the Committee deems appropriate (a) review and discuss with management the Company’s disclosures in the CD&A, and, based on this review, make a recommendation as to whether to include it in the Company’s annual report on Form 10-K and proxy statement relating to the Company’s annual meeting of shareholders, and (b) prepare a Compensation Committee Report for inclusion in the Company’s proxy statement or other applicable SEC filings. 4 Board Reports and Annual Evaluation. • Regularly report the Committee’s activities and any recommendations to the Board in such manner and at such times as the Committee or the Board deems appropriate. • Conduct an annual evaluation of the Committee’s performance. Committee Meetings and Action • A majority of the Committee members will be a quorum for the transaction of business. • The action of a majority of those present at a meeting at which a quorum is present will be the act of the Committee. • Any action that may be taken at a meeting of the Committee may be taken by written consent so long as the written consent is unanimously approved and filed with the Corporate Secretary. • The Company’s Chief Human Resources Officer will be the management liaison to the Committee with respect to matters concerning compensation and benefits. • The Committee may invite such members of management to its meetings as it deems appropriate.

Using GlasArmor panels, Ballisti-Wall® and Ballisti- Cover® solutions enable utility companies to add a superior level of protection to critical components and meet FERC security requirements within a modular, adaptable construction. 1 https://www.nbcnews.com/news/us-news/three-substations- attacked-washington-state-rcna63214 2 https://www.ferc.gov/sites/default/files/2020-04/E-4_10.pdf © 2023, All Rights Reserved Avient Corporation, 33587 Walker Road, Avon Lake, Ohio USA 44012 To learn more about Avient’s advanced composite solutions, visit www.avient.com/composites. https://www.nbcnews.com/news/us-news/three-substations-attacked-washington-state-rcna63214 https://www.nbcnews.com/news/us-news/three-substations-attacked-washington-state-rcna63214 https://www.ferc.gov/sites/default/files/2020-04/E-4_10.pdf http://www.avient.com/composites

APPLICATIONS • Medical devices • Drug delivery devices • Labware KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number level, reducing risk of change REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* * FDA/EU compliance information available upon request Copyright © 2023, Avient Corporation.

KEY CHARACTERISTICS • Manufactured under ISO 13485 procedures • Documented change control beyond CAS number, reducing risk of change • Can be used on common injection molding and extrusion machines—set-up support by a technical assistance team • Available for use in polyolefins, styrenics and copolymers • Can be combined with colorants REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 - USP and (incl. class VI) - European Pharmacopeia, monograph 3.1.3/ 3.1.5 (polyolefin packaging materials) - USP (polyethylene) - Elemental impurities as per ICH Q3D • Registered Drug Master File (Type III) and/or Device Master File • Food contact according to USA FDA and EU norms APPLICATION BULLETIN Sustainability Spotlight Healthcare use limitations apply—see below.

CONDUCTIVE PIPETTE TIP MANUFACTURER ACHIEVES SIGNIFICANT SAVINGS © 2021, All Rights Reserved Avient Corporation, 33587 Walker Road, Avon Lake, Ohio USA 44012 To learn more about Trilliant™ HC, contact Avient at +1.844.4AVIENT (1.844.428.4368) or visit us at avient.com. THE IMPACT For the manufacturer, Trilliant™ HC specialty engineered materials provided a number of advantages that contributed to the success of the new product line: • Reduced Cycle Time: The high flow properties of the Trilliant HC formulation allowed the manufacturer to produce warp-free parts that require less packing and cooling time, resulting in a 40% cycle time reduction. • Increased Production: Additionally, the high flow properties of the Trilliant HC formulation allowed for an increase in the number of cavities in the mold, resulting in a machine cost-per-part savings of over 30%. • Reduced Scrap Rate: The consistent conductivity, improved warp resistance, reduced flash, and improved durability provided by the Trilliant HC formulation meant less breakage, fewer rejects and a 40% reduction in scrap rate. • Total Manufacturing Cost Savings: Despite an increase I price per pound over the competition, the manufacturer’s total cash costs were reduced by over $45,000 on an annualized basis as a result of the proven, quantified savings in cycle time, productivity and scrap.

Because the material has never been combined or processed in this precise way, the “recipe” becomes a trade secret that the manufacturer saves for future use cases. Save and share the full guide as a PDF for future reference.

However, we continued to implement innovative waste minimization and energy savings projects that greatly reduced our overall environmental footprint. FINANCIAL INFORMATION Security analysts and representatives of financial institutions are invited to contact: Joe Di Salvo Vice President, Treasurer and Investor Relations Phone: 440-930-1921 Email: giuseppe.disalvo@polyone.com AUDITORS Ernst & Young LLP 950 Main Ave., Suite 1800 Cleveland, OH 44113 INTERNET ACCESS Information on PolyOne’s products and services, news releases, corporate governance, EDGAR filings, Reports on Forms 10-K and 10-Q, etc. as well as an electronic version of this annual report, are available on the Internet at www.polyone.com. THIS PAGE IS NOT PART OF POLYONE’S FORM 10-K FILING THIS PAGE IS NOT PART OF POLYONE’S FORM 10-K FILINGTHIS PAGE IS NOT PART OF POLYONE’S FORM 10-K FILING ROBERT M.

In accordance with US GAAP, the company expects the Distribution business will be classified as "held for sale" and reported as a discontinued operation in future filings. SEC Filings

A registration statement relating to these securities has been filed with the SEC Filings

General Purposes The general purposes of the Committee are to: • Oversee the Company’s overall executive compensation philosophy and objectives; • Discharge the Board’s responsibilities relating to compensation of the Company’s executive officers (for purposes of this Charter, “executive officers” means the Company’s Section 16 “officers” as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended); • Assist the Board in the discharge of its fiduciary responsibilities with regard to establishment of policies governing, and the implementation of, all aspects of executive officer compensation throughout the Company, including benefits and perquisites, and compensation for any other employees designated by the Committee for such purposes; • Discharge similar responsibilities with respect to the compensation of non-employee directors; • Review and discuss with management the Company’s disclosures in the Compensation Discussion and Analysis (the “CD&A”) required by rules and regulations of the Securities and Exchange Commission (the “SEC”) and recommend to the Board whether the CD&A should be included in the Company’s proxy statement or other applicable SEC filings; • Prepare a Compensation Committee Report for inclusion in the Company’s applicable filings with the SEC that complies with the rules and regulations of the SEC; and • Provide policy guidance and oversight on significant human resource policies and practices. 2 Duties and Responsibilities The Committee will: Executive Compensation and Incentives. • Oversee and maintain a competitive executive officer compensation program in order to attract and retain qualified executives and to provide incentives to executive officers that reward pay for performance in attaining the Company’s goals and objectives. • Review and approve a peer group of companies to be used for marketplace trend analysis and to assess the competitiveness of the Company’s total compensation opportunities for executive officers. • Review and approve corporate goals and objectives relevant to the Chief Executive Officer’s compensation; in conjunction with the evaluation conducted by the Board as described in the Company’s Corporate Governance Guidelines, evaluate the Chief Executive Officer’s performance in light of these goals and objectives; and determine and approve (or determine and approve, and recommend to the independent members of the Board for their determination and approval) the Chief Executive Officer’s compensation level based on this evaluation and comparable market data provided by an independent compensation consultant. • In determining the long-term incentive component of the Chief Executive Officer’s compensation, consider the Company’s performance and relative shareholder return, the value of similar incentive awards to chief executive officers at comparable companies, and the awards given to the Chief Executive Officer in the past. • Review and approve the compensation of other executive officers of the Company, including benefits and perquisites, taking into consideration the Company’s performance, comparable market data, the performance of each executive officer, and such other factors as may, in the Committee’s discretion, be appropriate. • In evaluating and making recommendations regarding, or determining and approving, executive compensation, the Committee shall consider the results of the most recent shareholder advisory vote on executive compensation (“Say on Pay Vote”) required by Section 14A of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). • With respect to incentive compensation plans and equity-based plans: • Make recommendations to the Board with respect to the approval of incentive compensation plans for executive officers and all equity-based plans. • Review and approve equity-based grants and awards, including long-term incentive plan awards, to officers, senior managers, key employees, and other employees of the Company and its subsidiaries under the Company’s equity-based plans. • Review and approve the performance criteria, target awards, payout criteria and like items for the Company’s long-term incentive compensation plans. • Review and approve (a) attainment levels for executive officers under the Company’s annual incentive plan; (b) payments to executive officers under the annual incentive plan; and (c) payments to executive officers under the Company’s long-term incentive compensation plans. • Administer the Company’s equity-based incentive compensation plans and other plans 3 adopted by the Board that contemplate administration by the Committee. • Review and approve special bonuses and/or other awards to executive officers on a case-by- case basis for outstanding performance. • Review and approve the terms of all employment agreements, management continuity agreements and change in control agreements for elected officers. Review and Discuss the CD&A; Compensation Committee Report. • With the assistance of management and any outside advisers the Committee deems appropriate (a) review and discuss with management the Company’s disclosures in the CD&A, and, based on this review, make a recommendation as to whether to include it in the Company’s annual report on Form 10-K and proxy statement relating to the Company’s 4 annual meeting of shareholders, and (b) prepare a Compensation Committee Report for inclusion in the Company’s proxy statement or other applicable SEC filings. Committee Meetings and Action • A majority of the Committee members will be a quorum for the transaction of business. • The action of a majority of those present at a meeting at which a quorum is present will be the act of the Committee. • Any action that may be taken at a meeting of the Committee may be taken by written consent so long as the written consent is unanimously approved and filed with the Corporate Secretary. • The Company’s Chief Human Resources Officer will be the management liaison to the Committee with respect to matters concerning compensation and benefits. • The Committee may invite such members of management to its meetings as it deems appropriate.